Beam Therapeutics investors back 2026 board slate

Beam Therapeutics Inc. reported results from its 2026 annual meeting of stockholders held on June 3, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Beam Therapeutics Inc. reported results from its 2026 annual meeting of stockholders held on June 3, 2026. Stockholders elected Class III directors John Evans, John Maraganore, Ph.D., and Christi Shaw to serve until the 2029 annual meeting, with each nominee receiving over 64.8 million votes in favor and substantial broker non-votes.

Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 85.75 million votes for and minimal opposition. In addition, they approved, on an advisory basis, the compensation of the company’s named executive officers, with approximately 71.5 million votes for and relatively low opposition and abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Votes for John Evans: 71,684,417 votes Votes for John Maraganore: 64,846,080 votes Votes for Christi Shaw: 65,652,959 votes +5 more

8 metrics

Votes for John Evans 71,684,417 votes Director election at 2026 annual meeting

Votes for John Maraganore 64,846,080 votes Director election at 2026 annual meeting

Votes for Christi Shaw 65,652,959 votes Director election at 2026 annual meeting

Auditor ratification for votes 85,754,272 votes Ratification of Deloitte & Touche LLP for 2026

Auditor ratification against votes 165,746 votes Ratification of Deloitte & Touche LLP for 2026

Say-on-pay for votes 71,546,749 votes Advisory approval of executive compensation

Say-on-pay against votes 985,066 votes Advisory approval of executive compensation

Broker non-votes on key items 13,419,659 votes Director elections and say-on-pay proposal

Key Terms

broker non-votes, independent registered public accounting firm, advisory basis, annual meeting of stockholders

4 terms

broker non-votes financial

"Broker Non-Votes | -------------------------------------------------------------------------------- John Evans ... 13,419,659"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

advisory basis financial

"The compensation of the Company’s named executive officers was approved, on an advisory basis"

annual meeting of stockholders financial

"held its 2026 annual meeting of stockholders (the “Annual Meeting”)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Beam Therapeutics (BEAM) shareholders decide at the 2026 annual meeting?

Beam Therapeutics shareholders elected three Class III directors, ratified Deloitte & Touche LLP as auditor for 2026, and approved named executive officer compensation on an advisory basis, based on strong support levels across all three proposals reported in the meeting results.

Which directors were elected at Beam Therapeutics’ 2026 annual meeting?

Shareholders elected John Evans, John Maraganore, Ph.D., and Christi Shaw as Class III directors. Each will serve until the 2029 annual meeting and until a successor is duly elected and qualified, reflecting continued support for the company’s existing board composition.

How strongly was Deloitte & Touche LLP approved as Beam Therapeutics’ auditor for 2026?

Deloitte & Touche LLP was ratified as Beam Therapeutics’ independent registered public accounting firm with 85,754,272 votes for, 165,746 against, and 304,989 abstentions, indicating very strong shareholder support and only minimal opposition for the 2026 fiscal year appointment.

Was Beam Therapeutics’ 2026 say-on-pay proposal approved by shareholders?

Yes. The advisory vote on compensation for Beam Therapeutics’ named executive officers received 71,546,749 votes for, 985,066 against, and 273,533 abstentions, with 13,419,659 broker non-votes, indicating shareholders generally supported the company’s executive compensation program for the year.

What were the approximate vote levels for Beam Therapeutics’ director nominees?

John Evans received 71,684,417 votes for; John Maraganore, Ph.D. received 64,846,080; and Christi Shaw received 65,652,959. Each nominee also recorded several hundred thousand votes against, modest abstentions, and 13,419,659 broker non-votes reported for the election item.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 04:05 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 03, 2026

    

Beam Therapeutics Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-39208	81-5238376
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

238 Main Street
Cambridge, Massachusetts		02142
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 857 327-8775

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	BEAM	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 3, 2026, Beam Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 17, 2026.

Proposal 1 – The following nominees were elected as Class III directors to serve on the Company’s board of directors until the Company’s 2029 annual meeting of stockholders, and until his or her successor has been duly elected and qualified, based on the following votes:



Nominee	For		Against		Abstentions		Broker Non-Votes
John Evans		71,684,417		864,042		256,889		13,419,659
John Maraganore, Ph.D.		64,846,080		7,701,591		257,677		13,419,659
Christi Shaw		65,652,959		6,893,102		259,287		13,419,659

Proposal 2 – The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 was ratified, based on the following votes:



For		Against		Abstentions
	85,754,272		165,746		304,989

Proposal 3 – The compensation of the Company’s named executive officers was approved, on an advisory basis, based on the following votes:



For		Against		Abstentions		Broker Non-Votes
	71,546,749		985,066		273,533		13,419,659

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			Beam Therapeutics Inc.

Date:	June 8, 2026	By:	/s/ John Evans
			John Evans Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document